Short Interest in Avalon GloboCare Corp. (NASDAQ:ALBT) Decreases By 80.4%

Avalon GloboCare Corp. (NASDAQ:ALBT) was the recipient of a significant drop in short interest during the month of January. As of January 15th, there was short interest totalling 22,400 shares, a drop of 80.4% from the December 31st total of 114,200 shares. Based on an average trading volume of 1,430,000 shares, the days-to-cover ratio is presently 0.0 days. Approximately 5.3% of the shares of the company are short sold.

Avalon GloboCare Stock Up 1.6 %

Shares of NASDAQ ALBT traded up $0.06 during mid-day trading on Tuesday, reaching $3.45. 12,885 shares of the company were exchanged, compared to its average volume of 47,328. The stock has a market capitalization of $3.76 million, a P/E ratio of -0.17 and a beta of 0.19. The company’s 50-day simple moving average is $3.41 and its 200-day simple moving average is $3.86. Avalon GloboCare has a twelve month low of $2.11 and a twelve month high of $21.60.

Avalon GloboCare (NASDAQ:ALBT) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($1.82) earnings per share for the quarter. The business had revenue of $0.35 million during the quarter.

About Avalon GloboCare

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells.